Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jul;18(7):982-8.
doi: 10.1016/j.bbmt.2012.04.006. Epub 2012 Apr 14.

Secondary treatment of acute graft-versus-host disease: a critical review

Affiliations
Review

Secondary treatment of acute graft-versus-host disease: a critical review

Paul J Martin et al. Biol Blood Marrow Transplant. 2012 Jul.

Abstract

Management of steroid-resistant or steroid-refractory acute graft-versus-host disease (aGVHD) poses one of the most vexing and difficult problems faced by transplantation physicians. In the current study, we used 10 criteria to evaluate 67 reports describing secondary treatment of patients with aGVHD. The goal of this exercise was not only to provide a critical summary of the literature but also to offer suggestions that could improve future studies. Areas especially in need of improvement include the use of a consistent treatment regimen, the assessment of response at a consistent prespecified time point, consideration of concomitant treatment in assessing response, documentation that selection bias was minimized, and the use of methods that test a formal statistical hypothesis based on a contemporaneous or historical benchmark. Our results suggest that previous published reports collectively offer little guidance in discerning the most effective treatments for patients with steroid-resistant or steroid-refractory aGVHD. Adherence to the proposed criteria in future reports would enable meaningful comparisons across studies and thereby accelerate progress in evaluating new treatments for patients with aGVHD.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure: The authors declare no financial conflicts of interest.

Figures

Figure 1
Figure 1
Treatments evaluated in prior reports. Treatments are listed in order of frequency among the 67 reports included in the literature review.
Figure 2
Figure 2
Distribution of scores representing the total number of criteria met by each report for the 67 studies included in the literature review.

References

    1. Cutler C, Antin JH. Manifestations and treatment of acute graft-versus-host disease. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, editors. Thomas' Hematopoietic Cell Transplantation. Oxford, UK: Wiley-Blackwell; 2009. pp. 1287–1303.
    1. Pavletic SZ, Vogelsang GB. Chronic graft-versus-host disease: clinical manifestations and therapy. In: Appelbaum FR, Forman SJ, Negrin R, Blume KG, editors. Thomas' Hematopoietic Cell Transplantation. Oxford, UK: Wiley-Blackwell; 2009. pp. 1304–1324.
    1. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109:4119–4126. - PMC - PubMed
    1. Martin PJ, Inamoto Y, Carpenter PA, Lee SJ, Flowers MED. Treatment of chronic graft-versus-host disease: past, present and future. Korean Journal of Hematology. 2011;46:153–163. - PMC - PubMed
    1. Hervé P, Wijdenes J, Bergerat JP, et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10) Blood. 1990;75:1017–1023. - PubMed

Publication types

MeSH terms